Argenx's VYVGART Approved for CIDP
This is a news story, published by Yahoo Finance, that relates primarily to European Commission/EC news.
drug discoveries news
For more drug discoveries news, you can click here:
more drug discoveries newsYahoo Finance news
For more news from Yahoo Finance, you can click here:
more news from Yahoo FinanceAbout the Otherweb
Otherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best health news, business news, entertainment news, and much more. If you like drug discoveries news, you might also like this article about
CIDP treatment. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest CIDP patients news, Argenx news, drug discoveries news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!
immunoglobulinsInsider Trading & Hedge Fund Data, and Investment Newsletter From Insider Monkey
•Health
Health
Argenx Secures EC Approval for Subcutaneous VYVGART in CIDP Treatment

75% Informative
European Commission/EC approved VYVGART (efgartigimod alfa) 1000 mg for subcutaneous/SC injection.
The approval is for its use as a monotherapy in adult patients with progressive or relapsing active chronic inflammatory demyelinating polyneuropathy/CIDP.
Argenx ( NASDAQ : ARGX ) is a commercial-stage biopharma company that develops various therapies for the treatment of autoimmune diseases.
VR Score
67
Informative language
63
Neutral language
17
Article tone
formal
Language
English
Language complexity
70
Offensive language
not offensive
Hate speech
not hateful
Attention-grabbing headline
not detected
Known propaganda techniques
not detected
Time-value
medium-lived
External references
5
Source diversity
1
Affiliate links
no affiliate links